Can pregabalin (Lyrica) cause brain fog?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Lyrica (pregabalin) can definitely cause brain fog.

Pregabalin commonly causes cognitive impairment that patients describe as "brain fog," manifesting primarily as difficulty with concentration and attention, along with confusion, amnesia, and somnolence. 1

Specific Cognitive Effects from FDA Data

The FDA label explicitly documents "thinking abnormal" as a dose-dependent adverse effect, which primarily consists of:

  • Difficulty with concentration/attention
  • Cognition and language problems
  • Slowed thinking

Incidence Rates Across Conditions

Neuropathic Pain (Diabetic Neuropathy):

  • "Thinking abnormal" occurred in 3% of pregabalin patients vs 0% placebo
  • Confusion: 3% vs 1% placebo
  • Amnesia: 2% vs 1% placebo
  • Somnolence: 12% vs 3% placebo 1

Postherpetic Neuralgia:

  • "Thinking abnormal": 6% vs 2% placebo
  • Confusion: 7% vs 0% placebo (notably high)
  • Amnesia: 4% vs 1% placebo 1

Epilepsy (as add-on therapy):

  • "Thinking abnormal": 8% vs 2% placebo
  • Confusion: 5% vs 2% placebo
  • Amnesia: 6% vs 2% placebo
  • These effects were dose-related, with 600 mg/day showing significantly higher rates 1

Dose-Dependent Pattern

The cognitive effects are clearly dose-dependent. At 600 mg/day, "thinking abnormal" occurred at rates 2-4 times higher than at 150 mg/day across all conditions. This means starting low and titrating slowly can minimize brain fog 1.

Clinical Significance

Cognitive impairment was significant enough that:

  • "Thinking abnormal" led to discontinuation in approximately 1-2% of patients
  • It was specifically listed among adverse reactions causing withdrawal at twice the rate of placebo
  • Confusion led to 2% discontinuation in postherpetic neuralgia trials 1

Important Caveats

Tolerance may develop: Most adverse reactions, including cognitive effects, were rated as "mild" or "moderate" in intensity, and some tolerance to dizziness and somnolence developed within a few weeks 2. However, the FDA label doesn't specifically state whether tolerance develops to cognitive impairment.

Withdrawal considerations: If brain fog is intolerable, pregabalin should be tapered rather than stopped abruptly, as withdrawal symptoms can occur 2.

Special populations at higher risk:

  • Elderly patients (cognitive effects may be more pronounced)
  • Patients taking other CNS depressants concurrently
  • Patients with renal insufficiency (requires dose reduction) 3, 1

The brain fog is real, documented, dose-dependent, and occurs in 3-8% of patients depending on the condition and dose. If a patient reports this side effect, consider dose reduction before discontinuation, as lower doses may provide benefit with less cognitive impairment.

Related Questions

What are the indications, dosing guidelines, contraindications, and side effects of Lyrica (pregabalin)?
What is the appropriate dosage of pregabalin for an adult?
How long does it take for pregabalin (Lyrica) to be eliminated from the body?
What pregabalin (Lyrica) dose is recommended for a patient with a glomerular filtration rate of 40 mL/min who is currently taking 75 mg three times daily?
What are the indications, mechanism of action, and alternative therapies for pregabalin (Lyrica)?
What is the optimal management of stasis dermatitis in a patient with amlodipine‑induced pedal edema who is also taking losartan?
What is the appropriate fluid volume and rate for initial management of diabetic ketoacidosis (DKA)?
How should a patient with hyperdynamic wall motion, a mild left ventricular outflow tract (LVOT) gradient, moderate aortic stenosis, and moderate aortic regurgitation be medically managed?
What is the appropriate management plan for a patient with hyperdynamic left‑ventricular wall motion, a mild left‑ventricular outflow tract (LVOT) gradient, and moderate aortic stenosis, moderate aortic regurgitation, and moderate mitral regurgitation?
What volume of intravenous isotonic crystalloid should be given in the first hour to a 60‑kg patient with diabetic ketoacidosis?
Should a low‑dose beta‑blocker be initiated in a patient with hyperdynamic left‑ventricular wall motion and a mild left‑ventricular outflow tract (LVOT) gradient, and what dosing regimen is recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.